newsfilter
← Latest News
GlobeNewswire·

Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma

– Overall response rate of 22% –– Disease control rate of 71% –– Median overall survival of 21 months –– Key topline data from ILLUMINATE-301 expected in Q1 2021 – EXTON, Pa., April 21, 2020 ...